A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512): stage 1 results

被引：0
|
作者：
Lee, Elizabeth [1 ]
Zhou, Yinglu [2 ]
Hendrickson, Andrea Wahner [3 ]
Fleming, Gini [4 ]
Konstantinopoulos, Panagiotis [1 ]
Krasner, Carolyn [1 ]
Stover, Elizabeth [1 ]
Horowitz, Neil [5 ]
Porter, Rebecca [1 ]
Wright, Alexi [1 ]
Matulonis, Ursula [1 ]
Xiong, Niya [2 ]
Sawyer, Hannah [1 ]
Tayob, Nabihah [2 ]
Liu, Joyce [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Data Sci, Boston, MA 02115 USA
[3] Mayo Clin, Comprehens Canc Ctr, Rochester, MN 55906 USA
[4] Univ Chicago, Med Oncol, Chicago, IL USA
[5] Brigham & Womens Hosp, Div Gynecol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB009/#156
引用
收藏
页码：A11 / A12
页数：2
相关论文
共 50 条
  • [1] A PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB IN RECURRENT OR PERSISTENT CLEAR CELL CARCINOMA OF THE OVARY
    Lee, Elizabeth
    Tayob, Nabihah
    Rimel, Bj
    Hendrickson, Andrea Wahner
    Nixon, Andrew
    Matulonis, Ursula
    Liu, Joyce
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A238 - A238
  • [2] Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
    McNamara, Blair
    Bellone, Stefania
    Demirkiran, Cem
    Hartwich, Tobias Max Philipp
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 48
  • [3] PHASE II TRIAL OF PEMBROLIZUMAB AND EPACADOSTAT IN RECURRENT CLEAR CELL CARCINOMA OF THE OVARY: AN NRG ONCOLOGY STUDY
    Gien, Lilian
    Enserro, Danielle
    Block, Matthew
    Waggoner, Steven
    Duska, Linda
    Hendrickson, Andrea Wahner
    Thaker, Premal
    Backes, Floor
    Bottsford-Miller, Justin
    Muller, Carolyn
    Disilvestro, Paul
    Covens, Allan
    Gershenson, David
    Moore, Kathleen
    Aghajanian, Carol
    Coleman, Robert L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A9 - A9
  • [4] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [5] Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer
    Bauer, Smadar
    Saad, Akram
    Greenhouse, Inbal
    Rapoport, Anna Ruth
    Shahar, Shir
    Barnatan, Tania
    Satchi-Fainaro, Ronit
    Shapira-Frommer, Ronnie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series
    Calo, Corinne A.
    Levine, Monica D.
    Brown, Morgan D.
    O'Malley, David M.
    Backes, Floor J.
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 46
  • [7] Preliminary results of sintilimab (Sin) plus bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial
    Liu, X.
    Xia, B.
    Zhang, W.
    Sun, L.
    Feng, C.
    Huang, Y.
    Gao, Y.
    Jiang, J.
    Li, G.
    Gao, Q.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S783 - S783
  • [8] Efficacy of sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial
    Gao, Qinglei
    Liu, Xingyu
    Xia, Bairong
    Zhang, Wei
    Sun, Li
    Feng, Cui
    Huang, Yi
    Gao, Yunong
    Jiang, Jie
    Li, Guiling
    Zhang, Yu
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S37 - S37
  • [9] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina
    Stepan, Daniel
    Li, Di
    Schmidt, Emmett
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
  • [10] Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
    Gien, Lilian T.
    Enserro, Danielle M.
    Block, Matthew S.
    Waggoner, Steven
    Duska, Linda R.
    Wahner-Hendrickson, Andrea E.
    Thaker, Premal H.
    Backes, Floor
    Kidd, Michael
    Muller, Carolyn Y.
    Disilvestro, Paul A.
    Covens, Allan
    Gershenson, David M.
    Moore, Kathleen N.
    Aghajanian, Carol
    Coleman, Robert L.
    GYNECOLOGIC ONCOLOGY, 2024, 186 : 61 - 68
12345